Impact of Patient, Intervention, and Setting Details on the Benefits and Harms of Psilocybin for Depression

The report is a product of the VA/HSR Evidence Synthesis Program.

Impact of Patient, Intervention, and Setting Details on the Benefits and Harms of Psilocybin for Depression

Takeaway: Reliable evidence on the efficacy and safety of psilocybin for depression remains limited to small trials conducted in relatively homogenous populations. Psilocybin paired with pre- and post-dosing psychotherapy likely improves short-term depression symptoms based on symptom rating scales, but the durability of these effects is unclear. Non-serious treatment harms such as headache, nausea, and dizziness appear to be common but resolve quickly. Serious adverse events appear to be rare, but because most studies excluded individuals at elevated risk for suicide, the effect of psilocybin treatment on suicidality remains unclear. Therapeutic alliance with treatment facilitators, the number of preparatory and dosing sessions, and a more intense psychedelic experience during dosing sessions may be associated with greater improvement in depression outcomes. However, evidence regarding variables that may influence treatment response is limited and should be considered exploratory. Overall, evidence on psilocybin treatment implementation is scant, but implementation plans should consider the resource-intensive nature of psylocibin treatment. Future research should focus on the effectiveness and potential harms of psilocybin treatment for depression under real-world conditions among diverse populations, compare its effectiveness to established treatments for depression, and investigate long-term effects. Research is also needed to understand psilocybin's potential influence on suicidality, and to examine whether individuals with psychiatric comorbidities, trauma histories, or other characteristics are more or less likely to benefit from psylocibin treatment and/or may benefit from modified treatment protocols.

Major depressive disorder is one of the most common health conditions affecting U.S. adults. Psilocybin, a naturally occurring psychedelic substance found in certain mushrooms, is currently being investigated as a novel treatment for depression. VHA is preparing for potential implementation of psilocybin treatment if it is approved by the FDA. To guide planning efforts, HSR's Evidence Synthesis Program (ESP) Coordinating Center in Portland, Oregon, conducted a systematic review on the therapeutic use of psilocybin for adults with depressive disorders, with an emphasis on synthesizing available evidence on the effects of patient selection and experience, intervention characteristics, and treatment setting on clinical outcomes. To identify relevant articles, the ESP team searched Medline, Embase, and PsycInfo through February 2026, hand-searched reference lists, and consulted experts.

Summary of Findings

• A total of 20 primary studies and 6 systematic reviews were included in this review.
• Most controlled trials were small and funded or supported by two biochemical companies that are developing psilocybin compounds for FDA approval.
• Psilocybin likely improves depression symptoms and may improve depression response and remission based on symptom rating scales in the short term, but long-term effects are unclear.
• Serious harms were rare. However, because most studies excluded individuals at elevated risk for suicide, the impact of psilocybin treatment on suicidality remains unclear.
• Non-serious harms such as blood pressure elevation, headache, nausea, and dizziness were common but brief in duration.
• Preliminary findings suggest that participant age, sex, and depression severity at baseline were not associated with depression outcomes following psilocybin treatment. Similarly, discontinuation of antidepressant medications prior to psilocybin treatment, and treatment expectancy were also not associated with treatment response.
• Developing a strong therapeutic alliance with treatment facilitators prior to psilocybin dosing; the number of preparatory and dosing sessions; and a more intense psychedelic experience and higher degree of mystical experiences during psilocybin dosing were associated with greater improvement in depression outcomes.
• The number and quality of therapy sessions may be particularly important for patients with PTSD or a history of trauma.
• The studies were conducted with relatively homogenous populations; treatment effectiveness and harms under real-world conditions are unclear.
• Evidence comparing psilocybin to another active treatment for depression is very limited.

Implications

Evidence on psilocybin for depression has greatly expanded in recent years, but remains limited to 8 small, controlled trials conducted in relatively homogenous populations. Findings from available evidence may have low applicability to more diverse and complex patients in VHA, including those with a higher baseline risk for suicide. Because psilocybin treatment is resource intensive-requiring specially trained staff and dedicated space to accommodate lengthy (6- to 8-hour) dosing appointments-one of the most important implementation challenges facing VHA might be how to ensure equitable access if the treatment is FDA approved. Research on effective implementation of psilocybin treatment is currently very limited.

Limitations

Existing evidence has several important limitations, which largely reflect that trials to date have been designed to evaluate the efficacy and safety of psilocybin, rather than test its effectiveness and potential harms under real-world conditions. Most trials were small, included homogeneous and relatively healthy patient populations, and had short follow-up periods.

Future Research

Research is needed to investigate the effectiveness and harms of psilocybin treatment in real-world conditions, and to compare the effectiveness of psilocybin to established treatments for depression. Future research should characterize which patients are most likely to benefit from or be harmed by psilocybin treatment; enhance understanding of psilocybin's effect on suicidality; and determine whether some patients with psychiatric comorbidities, a history of trauma, or other characteristics would benefit from modified psilocybin treatment protocols that allow for more flexibility with the number of psychotherapy or dosing sessions. Future clinical trials should include heterogeneous and complex populations, and should examine long-term outcomes and treatment effects at the subgroup level. Another important area for future research is to determine which components of the psilocybin treatment experience (e.g., the number of psilocybin doses, the number of preparatory sessions) have the greatest influence on depression outcomes.

Citation

Anderson JK, Beech EH, Baltich Nelson B, Wendell Z, Mackey KM. Impact of Patient, Intervention, and Setting Details on the Benefits and Harms of Psilocybin for Depression: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Systems Research, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-199; 2026.

To view the full report, go to https://vaww.hsrd.research.va.gov/publications/esp/psilocybin-depression.cfm (This report is available via intranet only.).